PPD clinical development and analytical services enable customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri...
PPD provides services to the biotech and biopharma industry. It will now become part of the Laboratory Products and Services unit of Thermo Fisher. With the takeover, Thermo Fisher intends to provide a complete suite of services across the clinical development spectrum, comprising scientific discovery...
Helping deliver life-changing therapies PPD clinical development and analytical services enable customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, al...
此前,Thermo Fisher承诺投资超过6亿美元,以扩大公司的生物加工生产能力,预计此举将帮助其生物制药客户满足与COVID-19大流行相关的短期需求,还能够开发对其他疾病可能有效的新疫苗和生物制剂。 继Icon于2月份以120亿美元收购PRA Health Sc...
PPD Outlines New Risk Factors Amid Pending Thermo Fisher Merger Neha GuptaNov 01, 2021, 09:59 PM A+ A- Global contract research organization PPD (PPD), will be acquired by Thermo Fisher Scientific (TMO) for $17.4 billion in cash, including the assumption of debt. The transaction is expecte...
The PPD™ clinical research business of Thermo Fisher Scientific is a global contract research organization (CRO) delivering clinical expertise for your product's success. Learn more about our life changing therapies.
StageAcq - P2P | Acquired Total Raised$71.05M Valuation$0000 View About PPD PPD operates as a global contract research organization (CRO) providing discovery, development, and post-approval services as well as compound partnering programs. The company's clients and partners include pharmaceutical, bi...
执行日常药物警戒活动,并遵循严格的时间表。药物警戒活动包括但不限于收集、监测、评估、评价、研究和跟踪安全信息。协调和执行药物警戒活动,如数据录入、不良事件编码和评估、病例审查、随访、报告跟踪和监管报告活动。有效地与各方合作,如:项目...
质粒信息: pPD95_67②线虫表达质粒 宿主分类:昆虫系列质粒 抗性:氨苄青霉素Ampicillin 菌株:DH5α 培养条件:37℃ 启动子:Lac/lac 复制子:pUCori 质粒大小:4532bp 质粒标签:SV40NLS,EGFP 表达宿主:线虫 5测序引物:M13
we believe that making such adjustments provides management and investors meaningful information to understand our operating performance and the ability to analyze financial and business trends on a period-to-period basis. Although we exclude amortization of acquired intangible assets from our non-GAAP ex...